Lataa...
Phase II and Coagulation Cascade Biomarker Study of Bevacizumab with or without Docetaxel in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma
PURPOSE: Treatment options are limited for advanced pancreatic cancer progressive after gemcitabine therapy. The vascular endothelial growth factor (VEGF) pathway is biologically important in pancreatic cancer, and docetaxel has modest anti-tumor activity. We evaluated the role of the anti-VEGF anti...
Tallennettuna:
| Päätekijät: | , , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2011
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3030655/ https://ncbi.nlm.nih.gov/pubmed/20458210 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0b013e3181d2734a |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|